Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics

Theravance Biopharma, Inc. - Ordinary Shares (TBPH): $16.89

-0.42 (-2.43%)

POWR Rating

Component Grades













Add TBPH to Watchlist
Sign Up

Industry: Biotech


of 487

in industry

TBPH Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for TBPH is -0.32 -- better than only 6.3% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.47 for Theravance Biopharma Inc; that's greater than it is for only 4.58% of US stocks.
  • Theravance Biopharma Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -24.03%, greater than the shareholder yield of just 10.15% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Theravance Biopharma Inc, a group of peers worth examining would be ASMB, CYCN, BLUE, ACIA, and FGEN.
  • TBPH's SEC filings can be seen here. And to visit Theravance Biopharma Inc's official web site, go to

TBPH Stock Price Chart Interactive Chart >

Price chart for TBPH

TBPH Price/Volume Stats

Current price $16.89 52-week high $31.35
Prev. close $17.31 52-week low $14.48
Day low $16.67 Volume 56,690
Day high $17.61 Avg. volume 350,142
50-day MA $18.48 Dividend yield N/A
200-day MA $19.45 Market Cap 1.08B

Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio

Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.

TBPH Latest News Stream

Event/Time News Detail
Loading, please wait...

TBPH Latest Social Stream

Loading social stream, please wait...

View Full TBPH Social Stream

Latest TBPH News From Around the Web

Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2020 Results - Earnings Call Transcript

Theravance Biopharma, Inc. (TBPH) Q4 2020 Earnings Conference Call February 23, 2021, 05:00 PM ET Company Participants Gail Cohen - VP, Corporate Communications and IR Rick Winningham - CEO Frank Pasqualone - Chief Commercial Operations Officer Brett Haumann - Chief Medical Officer Andrew Hindman - CFO Conference Call Participants Geoffrey...

SA Transcripts on Seeking Alpha | February 24, 2021

Theravance Biopharma Earnings Preview

Theravance Biopharma (NASDAQ:TBPH) releases its next round of earnings this Tuesday, February 23. Here is Benzinga's essential guide to Theravance Biopharma's Q4 earnings report. Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Sell-side analysts are expecting Theravance Biopharma's loss per share to be near $1.02 on sales of $20.85 million. In the same quarter last year, Theravance Biopharma announced EPS of $1.17 on revenue of $29.50 million. Why Analyst Estimates And Earnings Surprises Are Important Ana...

Yahoo | February 22, 2021

Theravance Biopharma to Participate in Upcoming Investor Conferences

Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows:

Yahoo | February 10, 2021

2 “Strong Buy” Stocks Trading at Steep Discounts

reward combination will work toward long-term advantage. So, how are investors supposed to distinguish between the names poised to get back on their feet and those set to remain down in the dumps? That’s what the pros on Wall Street are here for. Using TipRanks’ database, we pinpointed two beaten-down stocks the analysts believe are gearing up for a rebound.

Michael Marcus on TipRanks | January 14, 2021

Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 2:00 p.m. ET (11:00 a.m. PT/7:00 p.m. GMT). A webcast of the presentation may be accessed by visiting the "Investors" section of the Company's website at, and the replay will be archived for 30 days.

Yahoo | January 5, 2021

Read More 'TBPH' Stories Here

TBPH Price Returns

1-mo -11.52%
3-mo 2.93%
6-mo -2.48%
1-year -29.39%
3-year -39.79%
5-year 4.65%
YTD -4.95%
2020 -31.36%
2019 1.17%
2018 -8.25%
2017 -12.52%
2016 94.51%

Continue Researching TBPH

Here are a few links from around the web to help you further your research on Theravance Biopharma Inc's stock as an investment opportunity:

Theravance Biopharma Inc (TBPH) Stock Price | Nasdaq
Theravance Biopharma Inc (TBPH) Stock Quote, History and News - Yahoo Finance
Theravance Biopharma Inc (TBPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9357 seconds.